Validation of a patient-reported outcome measure for giant cell arteritis (2023)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Bromhead, A., …Robson, J. C. (2024). Validation of a patient-reported outcome measure for giant cell arteritis. Rheumatology, 63(1), 181-189. https://doi.org/10.1093/rheumatology/kead201

OBJECTIVES: GCA is systemic vasculitis manifesting as cranial, ocular or large vessel vasculitis. A prior qualitative study developed 40 candidate items to assess the impact of GCA on health-related quality of life (HRQoL). This study aimed to determ... Read More about Validation of a patient-reported outcome measure for giant cell arteritis.

CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2022). CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study. Value in Health, 25(7, Supplement), Page S305. https://doi.org/10.1016/j.jval.2022.04.105

POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis (2022)
Conference Proceeding
Robson, J., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Ndosi, M. (2022). POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis. . https://doi.org/10.1136/annrheumdis-2022-eular.1769

Background Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents a... Read More about POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis.

OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. C. (2022). OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac132.023

Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2021, November). Development and validation of a patient reported outcome measure for giant cell arteritis. Poster presented at ACR Convergence 2021, Online

Patient reported outcomes in large vessel vasculitides (2021)
Journal Article
Robson, J., Mackie, S., & Hill, C. (2021). Patient reported outcomes in large vessel vasculitides. Current Rheumatology Reports, 23(2), Article 7. https://doi.org/10.1007/s11926-020-00979-4

Purpose of Review: The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of systemic vas... Read More about Patient reported outcomes in large vessel vasculitides.

Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018 (2019)
Journal Article
Merkel, P. A., Direskeneli, H., Tugwell, P., Tómasson, G., Shea, B., Milman, N., …Hill, C. (2019). Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 46(9), 1198-1201. https://doi.org/10.3899/jrheum.181072

OBJECTIVE: The OMERACT Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV). METHODS: An international Delphi exercise conducted among investigators identified items considered... Read More about Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018.